APRE · Aprea Therapeutics, Inc.

Aprea Therapeutics has secured a significant capital infusion through an oversubscribed private placement, raising approximately $30 million in gross proceeds. This financing event, which closed on March 31, 2026, demonstrates investor confidence in the company's clinical-stage pipeline, particularly its lead candidate APR-1051, an oral WEE1 kinase inhibitor. The capital is earmarked for advancing the ongoing ACESOT-1051 study and expanding the evaluation of APR-1051 into specific biomarker-defined patient populations, namely uterine serous carcinoma and cyclin E-overexpressing, platinum-resistant ovarian cancer, with a goal of enrolling at least 50 patients. The transaction structure involved the sale of pre-funded warrants and warrants, providing immediate funding while setting future equity conversion terms. The involvement of institutional investors like Soleus Capital, alongside new participants Vestal Point Capital and Squadron Capital Management, underscores the strategic interest in Aprea's precision oncology approach. The company's commitment to filing a resale registration statement indicates planned liquidity for investors, though the securities remain unregistered and subject to resale restrictions until such registration is effective.